Armata Pharmaceuticals (ARMP) said Monday the US Food and Drug Administration has cleared an Investigational New Drug Application for AP-SA02 for treatment...
Armata Pharmaceuticals (ARMP) said Monday it has dosed the first person in the phase 1b/2a clinical trial of AP-SA02 to treat complicated Staphylococcus...
Armata Pharmaceuticals (ARMP) filed a registration statement with the US Securities and Exchange Commission on behalf of certain shareholders for the...
Armata Pharmaceuticals (ARMP) said Tuesday the US Food and Drug Administration has cleared its investigational drug application to launch a clinical trial...
Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of 0% and 98.21%,...
| Address | 4503 Glencoe Avenue Los Angeles, California 90292 |
| Phone | +1.310.655.2928 |
| Number of Employees | 31 |
| Recent SEC Filing | 08/11/2022 8-K |
| Chief Executive Officer & Director | Brian C. Varnum |
| Vice President-Operations | Duane A. Morris |
| Chief Financial & Accounting Officer | Erin Butler |
| Vice President-Clinical Development | Mina Pastagia |
| Price Open | $4.22 |
| Previous Close | $4.25 |
| 52 Week Range | $2.82 - 6.49 |
| Market Capitalization | $152.5 M |
| Shares Outstanding | 36.1 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 11/09/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.03 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | -549.64% |
| Return on Equity | -71.85% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
